McLean Screening Instrument for BPD (MSI-BPD): A Clinical Guide to Borderline Personality Disorder Screening

The McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) is a brief, 10-item self-report questionnaire designed to screen for the presence of borderline personality disorder (BPD). It was developed by Mary C. Zanarini and colleagues at McLean Hospital, a Harvard Medical School affiliate and one of the leading centers for personality disorder research in the world.

The MSI-BPD was created to address a specific clinical need: BPD is a common and serious psychiatric condition, but it is frequently underdiagnosed or misdiagnosed in clinical settings. Comprehensive diagnostic interviews — such as the Diagnostic Interview for DSM-IV Personality Disorders (DIPD-IV) or the Structured Clinical Interview for DSM (SCID-II) — are time-intensive and require specialized training. The MSI-BPD was designed as a rapid, cost-effective first step in identifying individuals who may warrant a more thorough diagnostic evaluation.

Published in 2003, the instrument has become one of the most widely used screening tools for BPD in both clinical and research settings. It is not a diagnostic instrument — it does not confirm or rule out BPD on its own — but it serves as a reliable gatekeeper that helps clinicians decide who should undergo further assessment.

The MSI-BPD assesses the core features of borderline personality disorder as defined by the DSM criteria. Each of the 10 items corresponds to a symptom domain associated with BPD, capturing the broad clinical picture of the disorder. The items map onto the nine DSM-5-TR diagnostic criteria for BPD, with one criterion (impulsivity) represented by two separate items to reflect the breadth of impulsive behaviors seen in clinical practice.

The domains assessed include:

• Frantic efforts to avoid abandonment — real or imagined fears of being left alone or rejected
• Unstable and intense interpersonal relationships — patterns of idealization and devaluation in close relationships
• Identity disturbance — a persistently unstable sense of self or self-image
• Impulsivity in at least two potentially self-damaging areas — this criterion is captured by two items, covering behaviors such as substance misuse, reckless spending, binge eating, or risky sexual behavior
• Recurrent suicidal behavior or self-harm — including gestures, threats, or self-mutilating behavior
• Affective instability — marked mood reactivity, including intense episodic dysphoria, irritability, or anxiety
• Chronic feelings of emptiness — a pervasive, enduring sense of inner void
• Inappropriate, intense anger — difficulty controlling anger or frequent displays of temper
• Transient, stress-related paranoid ideation or severe dissociative symptoms — brief episodes of losing touch with reality under stress

By covering each of these domains, the MSI-BPD provides a snapshot of whether an individual's experiences are consistent with the broader pattern of BPD symptomatology. Notably, the instrument asks about lifetime experiences rather than current symptoms, which is consistent with the trait-based nature of personality disorder assessment.

The MSI-BPD was developed and validated for use with adults (ages 18 and older) in psychiatric and clinical settings. Its original validation study was conducted with adult psychiatric outpatients and inpatients, and most subsequent research has used similar populations.

The instrument is appropriate for use in several contexts:

• Psychiatric outpatient clinics — as a routine part of intake assessment to flag individuals who may benefit from a comprehensive personality disorder evaluation
• Inpatient psychiatric settings — to identify BPD features among patients admitted for other presenting concerns such as depression, self-harm, or substance use disorders
• Primary care settings — where personality disorders are often unrecognized, the MSI-BPD can serve as a brief screen when clinicians suspect underlying personality pathology
• Research contexts — as a screening measure in epidemiological studies or clinical trials to identify potential participants with BPD

The MSI-BPD has also been studied in community samples, college student populations, and forensic settings, although the optimal cutoff score may vary across these groups. It has not been validated for use with children or young adolescents, and clinicians should exercise caution when applying it outside the populations in which it was originally tested.

Respondents need a reading level sufficient to understand straightforward questions about emotional and behavioral patterns. The instrument is available in English and has been translated and validated in several other languages, including Spanish, Dutch, Korean, and Italian, broadening its international applicability.

One of the key strengths of the MSI-BPD is its simplicity. The instrument consists of 10 yes-or-no questions that can typically be completed in under five minutes. It is a self-report measure, meaning the patient reads and answers the questions independently, without clinician guidance or structured interview.

Administration requires no specialized training. A clinician, research assistant, or intake coordinator can distribute the questionnaire on paper or in electronic format. The straightforward response format — each item requires only a "yes" or "no" answer — minimizes response burden and makes it accessible to individuals who may be in acute distress or have limited attention spans.

Because the MSI-BPD asks about lifetime experiences rather than current symptoms, it is generally appropriate to administer at any point during treatment, including during intake, follow-up, or transition of care. However, clinicians should be aware that acute psychiatric states — such as severe depression, psychosis, or intoxication — could affect a person's ability to accurately reflect on their lifetime patterns, potentially influencing the reliability of responses.

The instrument is designed to be scored and interpreted by a trained clinician. While scoring is simple (described in the next section), interpretation requires clinical judgment and should be situated within the broader context of the patient's history, presentation, and other assessment data.

Scoring the MSI-BPD is straightforward. Each "yes" response receives 1 point, and each "no" response receives 0 points. The total score ranges from 0 to 10.

The recommended cutoff score established in the original validation study is 7 or more. Individuals who endorse 7 or more items are considered to have screened positive for BPD, indicating that a comprehensive diagnostic evaluation is warranted.

At this cutoff of 7, the original study reported:

• Sensitivity of 0.81 — meaning the instrument correctly identified 81% of individuals who had BPD as confirmed by structured diagnostic interview
• Specificity of 0.85 — meaning 85% of individuals without BPD were correctly identified as not having the disorder

These are strong psychometric properties for a screening instrument. However, clinicians should understand what these numbers mean in practice:

• Sensitivity reflects the true positive rate — how well the instrument catches actual cases. A sensitivity of 0.81 means approximately 19% of individuals with BPD may be missed (false negatives).
• Specificity reflects the true negative rate — how well the instrument excludes those without the disorder. A specificity of 0.85 means approximately 15% of individuals without BPD may screen positive (false positives).

Some researchers have suggested using a lower cutoff of 5 or 6 in certain contexts, particularly in community samples or settings where maximizing sensitivity is more important than specificity (i.e., when it is critical not to miss potential cases). Lowering the cutoff increases sensitivity but decreases specificity, resulting in more false positives.

A positive screen is not a diagnosis. The MSI-BPD is designed to identify individuals who should be evaluated further using a comprehensive diagnostic interview. On the other hand, a negative screen does not definitively exclude BPD, particularly in individuals who may minimize or lack insight into their symptoms.

The MSI-BPD has been extensively studied since its publication in 2003, and the body of evidence supports its use as a valid and reliable screening instrument.

Construct validity: The items on the MSI-BPD directly correspond to DSM criteria for BPD, ensuring strong face validity and content validity. Studies have demonstrated that MSI-BPD scores correlate significantly with scores on other established BPD assessment tools, including the Structured Clinical Interview for DSM-IV Axis II (SCID-II) and the Revised Diagnostic Interview for Borderlines (DIB-R), supporting convergent validity.

Criterion validity: The original validation study by Zanarini and colleagues (2003) demonstrated that the MSI-BPD performed well against the gold standard of structured clinical interview, with the sensitivity and specificity values described above. Subsequent studies in diverse populations — including community samples, college students, and international populations — have generally replicated these findings, although the optimal cutoff score has varied somewhat across samples.

Internal consistency: The MSI-BPD has demonstrated acceptable internal consistency, with Cronbach's alpha values typically reported in the range of 0.74 to 0.90 across studies. This indicates that the items are measuring a coherent underlying construct.

Test-retest reliability: While fewer studies have examined test-retest reliability specifically, the available data suggest adequate stability over short time intervals, which is expected given that the instrument assesses trait-level patterns rather than fluctuating states.

Diagnostic efficiency: Research has consistently shown that the MSI-BPD performs comparably to longer screening instruments, such as the Personality Diagnostic Questionnaire (PDQ-4+) BPD scale, while requiring significantly less time and effort to administer. Its positive predictive value (the likelihood that a person who screens positive actually has BPD) depends heavily on the base rate of BPD in the population being screened — the instrument performs best in clinical populations where BPD prevalence is higher.

Like all screening instruments, the MSI-BPD has important limitations that clinicians and researchers should consider:

• It is a screening tool, not a diagnostic instrument. This cannot be overstated. The MSI-BPD identifies individuals who may have BPD and who should be evaluated further. It does not replace a comprehensive diagnostic assessment conducted by a trained mental health professional.
• Self-report biases. As a self-report measure, the MSI-BPD is subject to the same limitations as all self-report instruments. Individuals may over-report symptoms due to current distress, or under-report symptoms due to denial, limited self-awareness, or social desirability concerns. People with personality disorders may have particular difficulty with accurate self-assessment due to the ego-syntonic nature of some personality traits.
• Comorbidity and diagnostic overlap. Many of the features assessed by the MSI-BPD — such as affective instability, impulsivity, and identity disturbance — overlap with other psychiatric conditions, including bipolar disorder, complex PTSD, ADHD, and other personality disorders. A positive screen does not necessarily point to BPD specifically; it may reflect other conditions with overlapping features.
• Base rate considerations. The positive predictive value of the MSI-BPD is influenced by the prevalence of BPD in the population being screened. In settings where BPD is relatively uncommon (e.g., general primary care), a positive screen is more likely to be a false positive compared to specialized psychiatric settings where BPD is more prevalent.
• Cultural and linguistic considerations. Although the MSI-BPD has been translated into several languages, cross-cultural validation remains limited. Emotional expression, interpersonal patterns, and self-concept vary across cultures, and what constitutes "unstable relationships" or "identity disturbance" may be interpreted differently depending on cultural context.
• Binary response format. The yes/no format sacrifices nuance. An individual who experiences mild, occasional emptiness and someone with severe, chronic emptiness would both answer "yes" to the same item. The instrument does not capture severity or frequency of symptoms.
• Lifetime versus current symptoms. The MSI-BPD asks about lifetime experiences, which means individuals whose BPD symptoms have remitted or significantly improved over time may still screen positive. This is appropriate for identifying lifetime diagnosis but may be less informative about current clinical status.

In clinical practice, the MSI-BPD serves as a decision-support tool rather than a standalone assessment. Its results inform clinical judgment in several important ways:

Triaging for comprehensive evaluation: The primary use of the MSI-BPD is to identify individuals who should undergo a full diagnostic assessment for BPD. When a patient screens positive (score of 7 or above), the clinician typically follows up with a structured or semi-structured diagnostic interview — such as the SCID-5-PD, the DIPD-IV, or the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) — to confirm or rule out the diagnosis.

Enhancing clinical awareness: Even when a patient does not meet the recommended cutoff, a moderately elevated score (e.g., 4-6) can alert clinicians to the presence of borderline personality features that may complicate treatment for other conditions. For example, a patient presenting with major depressive disorder who endorses several BPD-related items may benefit from a treatment approach that addresses both mood symptoms and interpersonal or emotional regulation difficulties.

Treatment planning: While the MSI-BPD alone should not dictate treatment decisions, screening results can inform treatment planning. Evidence-based treatments for BPD — including Dialectical Behavior Therapy (DBT), Mentalization-Based Treatment (MBT), Transference-Focused Psychotherapy (TFP), and Schema Therapy — have demonstrated effectiveness, and early identification of BPD features can facilitate timely referral to appropriate, specialized care.

Research applications: In research settings, the MSI-BPD is frequently used to screen large numbers of potential participants efficiently, identifying those who should undergo further evaluation for inclusion in studies of BPD. This two-stage approach — brief screen followed by comprehensive interview — is a well-established methodology in psychiatric research.

Routine screening in high-risk populations: Some clinicians advocate for routine administration of the MSI-BPD in settings that serve populations at elevated risk for BPD, including eating disorder programs, substance use treatment centers, and self-harm crisis services. In these contexts, the instrument can help identify BPD features that might otherwise be overlooked when attention is focused on the presenting concern.

It is essential that clinicians communicate screening results to patients carefully and ethically. A positive screen should never be communicated as a diagnosis. Instead, clinicians should explain that the screening suggests further evaluation would be helpful and that a comprehensive assessment will provide a clearer clinical picture.

Understanding the clinical context of BPD helps illustrate why screening instruments like the MSI-BPD are so important. According to the DSM-5-TR, borderline personality disorder is characterized by a pervasive pattern of instability in interpersonal relationships, self-image, and affects, along with marked impulsivity, beginning by early adulthood and present in a variety of contexts. A diagnosis requires the presence of at least 5 of 9 specified criteria.

Prevalence estimates vary depending on the population studied. The DSM-5-TR estimates the median population prevalence of BPD at approximately 1.6%, but notes it may be as high as 5.9%. In clinical settings, BPD is significantly more common — estimated at approximately 6% of primary care patients, 10% of psychiatric outpatients, and 20% of psychiatric inpatients.

Despite this high prevalence in clinical populations, BPD is often underdiagnosed for several reasons:

• Its symptoms overlap with other disorders, including major depression, bipolar disorder, PTSD, and ADHD
• Clinician reluctance to assign a personality disorder diagnosis due to stigma concerns
• The time-intensive nature of comprehensive personality disorder assessment
• Patient presentation may focus on acute symptoms (e.g., self-harm, suicidality) rather than the underlying personality pattern

The MSI-BPD was developed specifically to address these barriers. By providing a quick, reliable first-pass screen, it lowers the threshold for identifying individuals who might benefit from a more thorough evaluation, ultimately supporting earlier and more accurate diagnosis.

The MSI-BPD was published by Zanarini and colleagues in the American Journal of Psychiatry in 2003. The full text of the 10 items is available in the original publication:

Zanarini, M. C., Vujanovic, A. A., Parachini, E. A., Boulanger, J. L., Frankenburg, F. R., & Hennen, J. (2003). A screening measure for BPD: The McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD). Journal of Personality Disorders, 17(6), 568–573.

The instrument is available for use in clinical and research settings. Clinicians interested in using the MSI-BPD should consult the original publication for the full item wording and scoring instructions. Some institutional and clinical websites also provide the instrument, but clinicians should verify that they are using the validated version.

When to seek professional help:

If you or someone you know experiences persistent patterns of emotional instability, intense and unstable relationships, chronic feelings of emptiness, impulsive behaviors that cause harm, recurrent self-harm, or an unstable sense of identity, it is important to seek evaluation from a qualified mental health professional — such as a psychologist, psychiatrist, or licensed clinical social worker — who has experience with personality disorders.

A screening tool like the MSI-BPD can raise important questions, but only a comprehensive clinical evaluation can provide answers. Effective, evidence-based treatments for BPD exist, and early identification is associated with better outcomes. If you are in crisis or experiencing thoughts of self-harm or suicide, contact the 988 Suicide and Crisis Lifeline (call or text 988 in the United States) or go to your nearest emergency room immediately.